NVS:NYSE
Novartis
145,47Ā $
arrow_downward
-1,36%(-2,01) 1Š
145,47Ā $
0,00% (0,00)
bedtimeŠŠ¾ŃŠ»Šµ Š·Š°ŠŗŃŃŃŠøŃ ŃŠµŃŃŠøŠø
Š¢Š¾ŃŠ³Šø Š·Š°ŠŗŃŃŃŃ: 24 Š°ŠæŃ., 16:00:02 GMT-4 · USD
search
ŠŃŠµ ŃŠøŠ¼Š²Š¾Š»Ń
1Š
5ŠŠ
1ŠŠŠ”
6ŠŠŠ”
Š”1ŠÆŠ
1ŠŠŠ
5ŠŠŠ¢
ŠŠŠŠ”
| Š”ŠøŠ¼Š²Š¾Š» | Š¦ŠµŠ½Š° | ŠŠ·Š¼ŠµŠ½ŠµŠ½ŠøŃ | ŠŠøŠ½Š°Š¼ŠøŠŗŠ° (%) |
|---|
insights_autoŠ”Š¾Š·Š“Š°Š½ŠøŠµ ŃŃŠ°ŃŠøŃŃŠøŠŗŠø Š“Š»Ń ŃŠøŠŗŠµŃŠ° NVSā¦
ŠŃŠŗŃŃŃŃ
146,03Ā $
ŠŃŃŠ¾ŠŗŠ°Ń
146,07Ā $
ŠŠøŠ·ŠŗŠ°Ń
144,05Ā $
Š ŃŠ½. ŠŗŠ°Šæ.
297,38Ā Š¼Š»ŃŠ“
Š”ŃŠµŠ“Š½. Š¾Š±ŃŠµŠ¼
1,83Ā Š¼Š»Š½
ŠŠ±ŃŠµŠ¼
1,30Ā Š¼Š»Š½
ŠŠøŠ²ŠøŠ“ŠµŠ½Š“
3,26Ā %
ŠŠ²Š°ŃŃŠ°Š»ŃŠ½ŃŠµ Š“ŠøŠ²ŠøŠ“ŠµŠ½Š“Ń
1,19Ā $
ŠŠŗŃ-Š“ŠøŠ²ŠøŠ“ŠµŠ½Š“Š½Š°Ń Š“Š°ŃŠ°
10 Š¼Š°Ń. 2026āÆŠ³.
ŠŠ¾ŃŃŃŠøŃŠøŠµŠ½Ń P/E
20,34
ŠŠ°ŠŗŃ. ŃŠµŠ½Š° Š·Š° 52 Š½ŠµŠ“.
170,46Ā $
ŠŠøŠ½. ŃŠµŠ½Š° Š·Š° 52 Š½ŠµŠ“.
104,93Ā $
ŠŃŠøŠ±ŃŠ»Ń Š½Š° Š°ŠŗŃŠøŃ
7,15Ā $
ŠŠµŃŠ°
0,51
ŠŠŗŃŠøŠø Š² Š¾Š±ŃŠ°ŃŠµŠ½ŠøŠø
2,03Ā Š¼Š»ŃŠ“
Š§ŠøŃŠ»Š¾ ŃŠ¾ŃŃŃŠ“Š½ŠøŠŗŠ¾Š²
75Ā ŃŃŃ.
ŠŠ¾Š²Š¾ŃŃŠø
ŠŠ· ŠøŃŃŠ¾ŃŠ½ŠøŠŗŠ¾Š² Š² ŠøŠ½ŃŠµŃŠ½ŠµŃŠµ
TradingView
·
2 Š“Š½Ń Š½Š°Š·Š°Š“
Novartis AG expected to post earnings of $2.00 a share - Earnings Preview
TradingView
·
2 Š“Š½Ń Š½Š°Š·Š°Š“
Novartis AG expected to post earnings of $2.13 a share - Earnings Preview
Yahoo Finance
·
2 Š“Š½Ń Š½Š°Š·Š°Š“
Novartis malaria treatment CoartemĀ® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Endpoints News
·
2 Š“Š½Ń Š½Š°Š·Š°Š“
Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?
ŠŃŠ¾ŃŠøŠ»Ń
Novartis ā ŃŃŠ°Š½ŃŠ½Š°ŃŠøŠ¾Š½Š°Š»ŃŠ½Š°Ń ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ°Š½ŠøŃ, Š¾Š“Š½Š° ŠøŠ· ŠŗŃŃŠæŠ½ŠµŠ¹ŃŠøŃ
Š² Š¼ŠøŃŠµ. ŠŠ¾Š¼ŠæŠ°Š½ŠøŃ ŃŠ°Š±Š¾ŃŠ°ŠµŃ Š² 140 ŃŃŃŠ°Š½Š°Ń
; ŃŃŠ°Š±-ŠŗŠ²Š°ŃŃŠøŃŠ° ŃŠ°ŃŠæŠ¾Š»Š¾Š¶ŠµŠ½Š° Š² ŠŠ°Š·ŠµŠ»Šµ, ŠØŠ²ŠµŠ¹ŃŠ°ŃŠøŃ. Novartis ā ŠæŠ¾Š»Š½Š¾ŠæŃŠ°Š²Š½ŃŠ¹ ŃŠ»ŠµŠ½ ŠµŠ²ŃŠ¾ŠæŠµŠ¹ŃŠŗŠ¾Š¹ Š¤ŠµŠ“ŠµŃŠ°ŃŠøŠø Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ¾Š¹ ŠæŃŠ¾Š¼ŃŃŠ»ŠµŠ½Š½Š¾ŃŃŠø Šø ŠŃŃŠ¾ŃŠøŠ°ŃŠøŠ¹, ŠŠµŠ¶Š“ŃŠ½Š°ŃŠ¾Š“Š½Š¾Š¹ ŃŠµŠ“ŠµŃŠ°ŃŠøŠø ŠŃŠ¾ŠøŠ·Š²Š¾Š“ŠøŃŠµŠ»ŠµŠ¹ ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ¾Š¹ ŠæŃŠ¾Š“ŃŠŗŃŠøŠø Šø ŠŃŃŠ¾ŃŠøŠ°ŃŠøŠ¹, Šø Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ¾Š³Š¾ ŠŃŃŠ»ŠµŠ“Š¾Š²Š°Š½ŠøŃ Šø ŠŃŠ¾ŠøŠ·Š²Š¾Š“ŠøŃŠµŠ»ŠµŠ¹ ŠŠ¼ŠµŃŠøŠŗŠø. Š ŃŠæŠøŃŠŗŠµ ŠŗŃŃŠæŠ½ŠµŠ¹ŃŠøŃ
ŠŗŠ¾Š¼ŠæŠ°Š½ŠøŠ¹ Š¼ŠøŃŠ° Forbes Global 2000 Š·Š° 2024 Š³Š¾Š“ Novartis Š·Š°Š½ŃŠ»Š° 99-Šµ Š¼ŠµŃŃŠ¾. Wikipedia
Š ŠŗŠ¾Š¼ŠæŠ°Š½ŠøŠø "Novartis"
ŠŠµŠ½ŠµŃŠ°Š»ŃŠ½ŃŠ¹ Š“ŠøŃŠµŠŗŃŠ¾ŃŠŠ°ŃŠ°Š½Ń ŠŠ°ŃŠ°ŃŠøŠ¼Ń
Š°Š½
ŠŠ¾Š»ŠøŃŠµŃŃŠ²Š¾ ŃŠ¾ŃŃŃŠ“Š½ŠøŠŗŠ¾Š²75,3Ā ŃŃŃ.
ŠŠ°ŃŠ° Š¾ŃŠ½Š¾Š²Š°Š½ŠøŃ29 ŃŠµŠ²Ń. 1996āÆŠ³.
ŠØŃŠ°Š±-ŠŗŠ²Š°ŃŃŠøŃŠ°ŠŠ°Š·ŠµŠ»Ń, ŠŠ°Š·ŠµŠ»Ń, ŠØŠ²ŠµŠ¹ŃŠ°ŃŠøŃ
Š”ŠµŠŗŃŠ¾Ń-
Š”Š°Š¹Ńnovartis.com
Š”Š¾Š·Š“Š°Š½Š½ŃŠ¹ ŠŠ ŠŗŠ¾Š½ŃŠµŠ½Ń Š¼Š¾Š¶ŠµŃ ŃŠ¾Š“ŠµŃŠ¶Š°ŃŃ Š¾ŃŠøŠ±ŠŗŠø. ŠŠ¾Š“ŃŠ¾Š±Š½ŠµŠµā¦
Š”ŠæŃŠ°Š²ŠŗŠ°ŠŃŠæŃŠ°Š²ŠøŃŃ Š¾ŃŠ·ŃŠ²ŠŠ¾Š½ŃŠøŠ“ŠµŠ½ŃŠøŠ°Š»ŃŠ½Š¾ŃŃŃŠ£ŃŠ»Š¾Š²ŠøŃŠŃŠŗŠ°Š· Š¾Ń Š¾Š±ŃŠ·Š°ŃŠµŠ»ŃŃŃŠ²